Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q8NEV9

UPID:
IL27A_HUMAN

ALTERNATIVE NAMES:
Interleukin-30; p28

ALTERNATIVE UPACC:
Q8NEV9; A0N0L2; Q6P676

BACKGROUND:
The protein Interleukin-27 subunit alpha, known alternatively as Interleukin-30 or p28, is integral to the immune system's response to pathogens. By forming IL-27 with EBI3, it modulates the immune system, balancing pro- and anti-inflammatory signals. It significantly impacts the differentiation and proliferation of T-cells, including naive and memory CD4 T-cells, and influences B-cell function. Its roles extend to affecting cytokine production, enhancing antitumor responses, and promoting antiangiogenic effects.

THERAPEUTIC SIGNIFICANCE:
The exploration of Interleukin-27 subunit alpha's functions offers promising avenues for therapeutic intervention. Its comprehensive involvement in immune modulation, suppression of inflammation, and contribution to antitumor immunity positions it as a target for developing treatments for autoimmune diseases and cancer.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.